DR. DAVID ALAN SAPERSTEIN, MD
Medical Practice at 112 Ave, Bellevue, WA

License number

Washington MD00038220

Personal information

See more information about DAVID ALAN SAPERSTEIN at radaris.com

Name

Address

Phone

David Saperstein, age 63

3410 47Th Ave NE, Seattle, WA 98105

David Saperstein

1200 University St, Seattle, WA 98101

(206) 387-5496

David Saperstein

2026 Fairview Ave E, Seattle, WA 98102

(206) 396-1471

Professional information

See more information about DAVID ALAN SAPERSTEIN at trustoria.com

Vitreoretinal Surgeon And Ophthalmic Drug Development Consultant

Position:

Partner Physician at Vitreoretinal Associates, Chief Medical Advisor at QLT Inc., Scientific Director at Usher III Initiative, Founder and Chief Medical Officer at Retinagenix, LLC

Location:

Seattle, Washington

Industry:

Biotechnology

Work:

Vitreoretinal Associates since Nov 2006 - Partner Physician QLT Inc. - Vancouver, Canada Area since 2012 - Chief Medical Advisor Usher III Initiative since Aug 2006 - Scientific Director Retinagenix, LLC since Mar 2004 - Founder and Chief Medical Officer QLT Inc. Nov 2006 - Jan 2010 - Interim Chief Medical Officer Light Sciences 2002 - 2006 - Consultant Washington University School of Medicine Mar 2000 - Sep 2006 - Associate Professor University of Washington 2000 - 2006 - Associate Professor Emory University School of Medicine Jul 1995 - Feb 2000 - Assistant Professor, Ophthalmology

Education:

Pennsylvania State University College of Medicine 1983 - 1987
Doctor of Medicine (MD) The George Washington University 1978 - 1983
BSEE, Electrical Engineering/Bioengineering

Skills:

Biotechnology, Lifesciences, Clinical Research, Clinical Trials, Biochemistry, Cell Biology, Ophthalmology, Medical Devices, Drug Discovery, Pharmaceutical Industry, Clinical Development, Molecular Biology

Dr. David A Saperstein, Seattle WA - MD (Doctor of Medicine)

Specialties:

Ophthalmology

Address:

Vitreoretinal Associates
1221 Madison St SUITE 1002, Seattle 98104
(800) 331-3719 (Phone), (206) 215-3870 (Fax)
Vitreoretinal Associates - Bellevue
1750 112Th Ave NE SUITE D050, Bellevue 98004
(206) 215-3850 (Phone)

Certifications:

Ophthalmology, 2006

Awards:

Healthgrades Honor Roll

Languages:

English, Spanish

Hospitals:

Vitreoretinal Associates
1221 Madison St SUITE 1002, Seattle 98104
Vitreoretinal Associates - Bellevue
1750 112Th Ave NE SUITE D050, Bellevue 98004
Swedish Medical Center/First Hill
747 Broadway, Seattle 98122

Education:

Medical School
Penn St University Hershey Med Center
Graduated: 1987
Brockton Hospital Boston University
Graduated: 1988
Saint Louis University
Graduated: 1993
Emory University School Of Med
Graduated: 1995

David Alan Saperstein, Seattle WA

Specialties:

Ophthalmology

Work:

Vitreoretinal Associates Seattle
1221 Madison St, Seattle, WA 98104 Vitreoretinal Associates of Washington
1750 112Th Ave NE, Bellevue, WA 98004 Vitreoretinal Associates Washington
215 E George Hopper Rd, Burlington, WA 98233 Vitreoretinal Associates
4915 25Th Ave NE, Seattle, WA 98105

Education:

Pennsylvania State University (1987), National Eye Institute, National Institutes of Health Bethesda, MD (1990) *Ophthalmology

Retinoid Replacements And Opsin Agonists And Methods For The Use Thereof

US Patent:

2013007, Mar 21, 2013

Filed:

Sep 14, 2012

Appl. No.:

13/619607

Inventors:

Krzysztof Palczewski - Bay Village OH, US
David A. Saperstein - Seattle WA, US

Assignee:

UNIVERSITY OF WASHINGTON - Seattle WA

International Classification:

A61K 31/11, A61P 27/02

US Classification:

514703

Abstract:

Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.

Retinoid Replacements And Opsin Agonists And Methods For The Use Thereof

US Patent:

2013007, Mar 21, 2013

Filed:

Sep 14, 2012

Appl. No.:

13/619758

Inventors:

Krzysztof PALCZEWSKI - BAY VILLAGE OH, US
David A. SAPERSTEIN - SEATTLE WA, US

Assignee:

UNIVERSITY OF WASHINGTON - Seattle WA

International Classification:

A61K 31/11

US Classification:

514703

Abstract:

Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.

Retinoid Replacements And Opsin Agonists And Methods For The Use Thereof

US Patent:

2013019, Aug 1, 2013

Filed:

Dec 7, 2012

Appl. No.:

13/708558

Inventors:

University of Washingon - Seattle WA, US
David A. Saperstein - Seattle WA, US

Assignee:

University Of Washington - Seattle WA

International Classification:

A61K 31/07, A61K 31/435, A61K 31/695, A61K 31/11, A61K 31/382

US Classification:

514 63, 514725, 514703, 514701, 514432, 514277, 514729

Abstract:

Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.

Methods For The Treatment And Prevention Of Age-Related Retinal Dysfunction

US Patent:

8324270, Dec 4, 2012

Filed:

Feb 10, 2009

Appl. No.:

12/368427

Inventors:

Tadao Maeda - Mayfield Heights OH, US
David Saperstein - Seattle WA, US
Krzysztof Palczewski - Bay Village OH, US

Assignee:

University of Washington - Seattle WA

International Classification:

A61K 31/215, A61K 31/21

US Classification:

514529, 514506, 514914

Abstract:

A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C-Cmonocarboxylic acids and C-Cpolycarboxylic acids.